SCHEMBL3979965

SCHEMBL3979965

Cc1ccc(C)c(-n2nc(-c3ccc(F)cc3)cc2Nc2nc(C)cc(C)c2C(N)=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.41
TP53 P04637 1/20 0.41
BLM P54132 1/20 0.41
MAPT P10636 4/20 0.40
KDM4E B2RXH2 4/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 2/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
HTT P42858 1/20 0.38
GRM2 Q14416 1/20 0.35
NPY5R Q15761 1/20 0.35
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973998 0.94 HSD17B10 (0.44) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3981181 0.91 KDM4E (0.48) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3975648 0.90 HSD17B10 (0.48) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3975028 0.87 SMN1; SMN2 (0.38) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3979001 0.82 MAPT (0.39) MEN1KMT2AALDH1A1TP53MAPT
SCHEMBL3974034 0.82 ALDH1A1 (0.49) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3976307 0.82 MEN1 (0.47) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3975657 0.81 MEN1 (0.45) HSD17B10MEN1KMT2AALDH1A1TP53
SCHEMBL3979999 0.81 RAB9A (0.47) MEN1KMT2AALDH1A1TP53MAPT
SCHEMBL3973215 0.77 MAPT (0.41) ALDH1A1TP53MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP HSD17B10 320/4885MEN1 3766/4885KMT2A 3923/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP HSD17B10 320/4885MEN1 3766/4885KMT2A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.